Dexcom reported a strong fourth quarter in 2023, with revenue increasing by 27% year-over-year to $1.03 billion. GAAP operating income increased significantly, and net income saw a substantial rise. The company also provided annual guidance for 2024.
Revenue grew 27% year-over-year to $1.03 billion.
U.S. and International revenue both grew by 27%.
GAAP operating income increased by 560 basis points compared to Q4 2022.
Submitted Stelo, Dexcom’s new glucose sensor for people with type 2 diabetes who do not use insulin, to the FDA for review.
The company is reiterating fiscal year 2024 guidance for Revenue, Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin, and establishing Adjusted EBITDA Margin guidance.
Visualization of income flow from segment revenue to net income